September JAAD: Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up)

As a subscriber to Dialogues in Dermatology premium channel, you will receive new podcasts weekly and can earn CME credit. Listen each week as dermatologists discuss clinical treatments and the latest in dermatology. Dialogues in Dermatology is brought to you by the American Academy of Dermatology.

Share September JAAD: Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up)

Sign up to save your podcasts

September JAAD: Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up)

September JAAD: Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up)

More shows like AAD's Dialogues in Dermatology

JAMA Clinical Reviews

Hidden Brain

Pod Save America

White Coat Investor Podcast

JAMA Dermatology Author Interviews

Learn Skin with Dr. Raja and Dr. Hadar

The Grenz Zone

Dermasphere - The Dermatology Podcast

SmartLess

The Ezra Klein Show

Derms and Conditions

We Can Do Hard Things

Cutaneous Miscellaneous: The Dermatology Residents Podcast

The Practical Dermatology Podcast

Skin Deep MDs with Dr. Mamina Turegano, Dr. Lindsey Zubritsky and Dr. Jenny Liu